Post results we have revised FY21E revenues upwards by 3.7% but FY22E downwards by 5.8% (lower volume assumptions). PAT for FY21E stands doubled and up by 28.3% for FY22E due to beat on EBITDA/ton & lower interest burn. Going ahead, along with volume growth we also expect EBITDA/ton to expand steadily led by operating leverage, cost savings and better product mix. Simultaneously balance sheet will also gain strength due to combined effect of shorter NWC cycle (10 days v/s 17 days FY20), deleveraging and high cash generation. At CMP, the stock is trading at EV/EBITDA of 8.1x FY22E. Our previous TP of Rs 1961 is achieved but we...